NADAC acquisition cost data for SINGULAIR 10 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00006911731 | $7.70 | 2022-01-14 | Rx |
| 00006911754 | $7.70 | 2022-01-14 | Rx |
| 78206017201 | $7.70 | 2022-01-14 | Rx |
| 78206017202 | $7.70 | 2022-01-14 | Rx |
| 00006911731 | $7.70 | 2022-01-14 | Rx |
| 00006911754 | $7.70 | 2022-01-14 | Rx |
| 78206017201 | $7.70 | 2022-01-14 | Rx |
| 78206017202 | $7.70 | 2022-01-14 | Rx |
| 00006911731 | $7.70 | 2022-01-14 | Rx |
| 00006911754 | $7.70 | 2022-01-14 | Rx |
Generic: Montelukast Sodium | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | 4,689 | N/A |
| 2020 | N/A | N/A | 4,453 | N/A |
| 2021 | $1.9M | 3,801 | 3,824 | $7.47 |
| 2022 | $6.8M | 13,748 | 3,201 | $8.02 |
| 2023 | $6.6M | 12,250 | 2,783 | $8.71 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $875.0K | 1,828 | 363 |
| California | $718.4K | 1,284 | 295 |
| South Carolina | $417.6K | 628 | 209 |
| New Jersey | $412.0K | 795 | 169 |
| Pennsylvania | $405.2K | 766 | 167 |
| Florida | $402.9K | 754 | 179 |
| Texas | $267.4K | 491 | 125 |
| Massachusetts | $212.8K | 386 | 88 |
| North Carolina | $204.8K | 417 | 88 |
| Ohio | $184.0K | 319 | 78 |
| Illinois | $175.0K | 302 | 81 |
| Connecticut | $168.5K | 260 | 66 |
| Virginia | $159.3K | 261 | 69 |
| Georgia | $144.8K | 252 | 56 |
| Michigan | $134.1K | 236 | 60 |
| Puerto Rico | $115.0K | 356 | 66 |
| Minnesota | $109.6K | 201 | 48 |
| Washington | $109.3K | 209 | 46 |
| Indiana | $104.1K | 178 | 45 |
| Wisconsin | $96.7K | 166 | 38 |
| Maryland | $80.5K | 150 | 33 |
| Kentucky | $80.4K | 140 | 35 |
| Arizona | $79.8K | 126 | 40 |
| Tennessee | $71.9K | 118 | 32 |
| Missouri | $71.1K | 127 | 27 |
| Iowa | $68.7K | 127 | 26 |
| Maine | $65.5K | 95 | 24 |
| Louisiana | $57.8K | 116 | 24 |
| Oklahoma | $54.8K | 92 | 21 |
| New Hampshire | $49.5K | 86 | 22 |
| Nevada | $44.7K | 77 | 18 |
| Kansas | $41.1K | 74 | 16 |
| Alaska | $38.2K | 60 | 16 |
| Oregon | $37.1K | 86 | 14 |
| Alabama | $36.5K | 99 | 19 |
| Delaware | $34.0K | 61 | 14 |
| Hawaii | $30.2K | 43 | 13 |
| Colorado | $29.3K | 53 | 12 |
| Mississippi | $26.0K | 43 | N/A |
| West Virginia | $25.9K | 44 | 11 |
| Arkansas | $24.6K | 62 | 11 |
| Nebraska | $21.9K | 34 | N/A |
| New Mexico | $21.1K | 43 | N/A |
| Vermont | $20.7K | 35 | N/A |
| Montana | $20.2K | 30 | N/A |
| South Dakota | $17.1K | 31 | N/A |
| North Dakota | $14.8K | 28 | N/A |
| District of Columbia | $13.4K | 27 | N/A |
| Wyoming | $8.7K | 14 | N/A |
| Idaho | $7.1K | 12 | N/A |
| Rhode Island | $6.2K | 14 | N/A |
| Utah | $6.1K | 14 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.